Kinesiomeda - Company finances
|
EUR
|
2022
From: 2022-10-19
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | - | 10,445 | 8,428 | 14,987 |
| Profit before tax | -2,346 | 2,442 | 246 | 6,772 |
| Net profit | -2,346 | 2,442 | 234 | 6,772 |
| Equity | 1,154 | 3,596 | 3,830 | 6,103 |
| Liabilities | 451 | 2,590 | 2,233 | 3,253 |
| Non-current assets | 1,135 | 809 | 4,183 | 6,610 |
| Current assets | 470 | 5,377 | 1,880 | 2,746 |
| Total assets | 1,605 | 6,186 | 6,063 | 9,356 |
|
Taxes paid
|
||||
| STI taxes | - | 147 | 5 | 24 |
|
Financial indicators
|
||||
| Revenue change y/y | - | - | -19.3% | +77.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -146.2% | 39.5% | 3.9% | 72.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -203.3% | 67.9% | 6.1% | 111.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 23.4% | 2.8% | 45.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 23.4% | 2.9% | 45.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.7 | 0.6 | 0.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Kinesiomeda - Social security debts
The company had no debts to Sodra
Kinesiomeda - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Kinesiomeda, MB (code 306161771) is a Lithuanian small partnership engaged in other human health activities n.e.c. In the latest financial year, 2025, the company generated revenue of €15.0K and net profit of €6.8K, resulting in a profit margin of 45.2%. This was a strong improvement from 2024, when revenue was €8.4K and net profit €234, following 2023, when revenue reached €10.4K and net profit €2.4K. Revenue therefore declined in 2024 and then rose sharply in 2025, while profitability followed a similar pattern, with a much stronger result in the latest year. At the end of 2025, total assets stood at €9.4K, equity at €6.1K and liabilities at €3.3K. The equity ratio was 65.2% and debt-to-equity was 0.53, indicating a solid capital structure with moderate leverage. Asset turnover was 1.60x, showing that the company used its asset base efficiently relative to revenue. Returns on equity and assets were very strong in 2025, reflecting the low absolute scale of the balance sheet.